RxDoctor Payments Data

Jason Fletcher, DO

Internal Medicine · Long Beach, CANPI 1487810131

Payments from drug & device makers

$611in general payments, 2019–2025

Across 33 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$128
  • Sunovion Pharmaceuticals Inc.$93
  • Amgen$67
  • Aurinia Pharma U.S., Inc.$60
  • Otsuka America Pharmaceutical, Inc.$46
  • Ultragenyx Pharmaceutical Inc.$41
  • plus $176 from 7 others

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$611 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$104,434
Medicare patients
184
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$78,890
XifaxanRifaximin20$30,098
EliquisApixaban50$20,817
NuedextaDextromethorphan Hbr/Quinidine25$19,604
FarxigaDapagliflozin Propanediol49$17,268
AptiomEslicarbazepine Acetate26$16,501
DapagliflozinDapagliflozin Propanediol51$13,270
JardianceEmpagliflozin33$9,743
Combivent RespimatIpratropium/Albuterol Sulfate12$6,331
Breo ElliptaFluticasone/Vilanterol11$4,843
TrulicityDulaglutide12$3,867
Insulin Lispro Kwikpen U-100Insulin Lispro34$2,053
Oxcarbazepine23$1,744
Mirtazapine50$1,739
Rasagiline Mesylate21$1,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$128$17,26849 claims
Sunovion Pharmaceuticals Inc.Aptiom$93$16,50126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →